
Opinion|Videos|April 4, 2025
C-Peptide and Early Type 1 Diabetes Detection
A panelist discusses how C-peptide serves as a critical biomarker of endogenous insulin production, providing clinicians with valuable insights into remaining beta cell function that can guide personalized treatment approaches and help predict disease progression in patients with type 1 diabetes (T1D).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- C-peptide is increasingly recognized as a marker for beta cell function. Can you explain the role of C-peptide in practice?
- How does early identification of T1D change the trajectory of disease management?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Retatrutide shows substantial weight loss, glycemic control in obesity and type 2 diabetes | ADA 2026
2
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
3
CONNECT data support CGM use in non-insulin type 2 diabetes management | ADA 2026
4
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2026
5






























